AbbVie Inc (ABBV)vsRxsight Inc (RXST)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
RXST
Rxsight Inc
$6.81
-5.02%
HEALTHCARE · Cap: $295.88M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 45379% more annual revenue ($61.16B vs $134.48M). ABBV leads profitability with a 6.9% profit margin vs -29.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
RXST
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+73.2%
Fair Value
$30.01
Current Price
$6.81
$23.20 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -14.0% — below average capital efficiency
Revenue declined 18.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : RXST
The strongest argument for RXST centers on Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : RXST
The primary concerns for RXST are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while RXST is a turnaround play — different risk/reward profiles.
RXST carries more volatility with a beta of 1.21 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 29/100). RXST offers better value entry with a 73.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Rxsight Inc
HEALTHCARE · MEDICAL DEVICES · USA
Rxsight Inc. is an innovative healthcare technology company focused on revolutionizing vision correction through cutting-edge diagnostic and surgical techniques in refractive eye surgery. By leveraging proprietary software and precision-guided laser technology, Rxsight enhances patient outcomes and elevates the quality of life for individuals seeking vision correction. The company boasts a strong intellectual property portfolio and strategic partnerships, reinforcing its competitive edge in the rapidly growing ophthalmic market. With a steadfast commitment to innovation and excellence, Rxsight is well-positioned for substantial growth and transformative impact in the evolving landscape of eye care.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?